RSS

Polpharma Group

EPIRUS Biopharmaceuticals and Polish generics company Polpharma Group have struck a multi-product, multi-region profit-sharing deal for select EPIRUS biosimilars, representing $6 billion in innovator sales in the specified territories. more

News